Augmentation of antitumour activity of defucosylated chimeric anti‐CCR4 monoclonal antibody in SCID mouse model of adult T‐cell leukaemia/lymphoma using G‐CSF
Open Access
- 17 January 2008
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 140 (5) , 586-589
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphomaLeukemia, 2006
- CCR4 as a novel molecular target for immunotherapy of cancerCancer Science, 2006
- Potent antibody therapeutics by designNature Reviews Immunology, 2006
- Natural history of adult T-cell leukemia/lymphoma and approaches to therapyOncogene, 2005
- The CC Chemokine Receptor 4 as a Novel Specific Molecular Target for Immunotherapy in Adult T-Cell Leukemia/LymphomaClinical Cancer Research, 2004
- The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody ImmunotherapyJournal of Experimental Medicine, 2004
- Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and LymphomaCancer Research, 2004
- Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.2003
- Serial Transplantation of Adult T Cell Leukemia Cells into Severe Combined Immunodeficient MiceJapanese Journal of Cancer Research, 1996
- Adult T-cell leukemia: clinical and hematologic features of 16 casesBlood, 1977